women in lab

What is LucentAD® Complete

LucentAD® Complete is a highly sensitive blood test that measures multiple Alzheimer’s related biomarkers, including p-Tau 217, AB 42/40, GFAP, and NfL. This multi-analyte algorithmic approach reduces the diagnostic uncertainty associated with single biomarker tests, making it an essential tool for earlier Alzheimer’s disease evaluation.

Key Benefits

icon chart

Comprehensive Biomarker Panel

Measures multiple Alzheimer’s related proteins

icon target

Ultra-Sensitive
Detection

Enables early and accurate assessment

icon calender

Non-Invasive, Accessible, and Scalable

A simple blood-based alternative to lumbar punctures or PET scans

Learn more about Simoa® Technology

What does LucentAD® Complete Measure?

LucentAD® Complete detects multiple key Alzheimer’s biomarkers in the blood, providing a comprehensive risk assessment of the likelihood of amyloid pathology.

  • p-Tau 217: Highly specific to amyloid pathology and early Alzheimer’s changes.
  • Amyloid Beta (AB42/40 Ratio): Directly correlates with amyloid plaque burden in the brain.
  • Neurofilament Light (NfL): A marker of neurodegeneration.
  • Glial Fibrillary Acidic Protein (GFAP): Indicates astrocyte activation, an early response to amyloid deposition.

Why these biomarkers matter:

  • p-Tau 217, Amyloid Beta (AB42/40 Ratio), NfL and GFAP: together improve the accuracy of amyloid status classification.
  • Multi-Analyte approach reduces the diagnostic “gray zone” by two-thirds, improving certainty, and providing a definitive result for more patients.

*GFAP is offered pursuant to a license from Banyan Biomarkers, Inc. Banyan GFAP® is a registered trademark of Banyan Biomarkers.

Read the clinical evidence

How LucentAD® Complete Works

icon number one

Order the test

Easily request through portal or paper requisition

icon number second

Blood Sample Collection

A simple blood draw at your practice or a partner lab

icon number three

Simoa® Analysis

Ultra-sensitive biomarker quantification

icon number four

Receive Results

Delivered within 10 business days for clinical interpretation

Sign up to offer LucentAD® Complete

LucentAD® Complete

Special Instructions

This assay currently is not available in New York State

 

Expected Turnaround Time

10 business days

 

Related Documents

Sample Report

White Paper

 

Automated robotic arm handling liquid samples in laboratory

Clinical Validation and Supporting Research

  • Backed by leading Alzheimer’s research
  • Proven correlation with CSF and PET imaging for amyloid detection
  • Reduces the diagnostic “gray zone” by nearly 3-fold, improving classification certainty.

Read the research

Key validation metrics

  • 90% Sensitivity – Identifies amyloid pathology with high accuracy
  • 90% Specificity – Effectively rules out non-Alzheimer’s conditions
  • 90% Accuracy
  • 87% Negative Predictive Value – High confidence in negative results
  • 92% Positive Predictive Value – High confidence in positive results

LucentAD® Complete was validated in multiple clinical cohorts, including:

  • Amsterdam Dementia Cohort (CSF-based validation)
  • BioHermes Trial (PET-based validation)
  • ADNI Cohort (Longitudinal validation)

Test specifications

Using and Interpreting the Results

LucentAD® Complete reports an Amyloid risk score ranging from 0-100, helping classify the likelihood of Alzheimer’s-related pathology.

Amyloid Risk Score Interpretation
<45 Low likelihood of amyloid pathology. Other causes should be considered
45-70 Intermediate likelihood. Further testing (CSF/PET) may be required
>70 High likelihood of amyloid pathology. Consistent with Alzheimer’s disease

LucentAD® Complete is not a standalone diagnostic test. It is meant to be used alongside clinical assessments for a comprehensive diagnostic evaluation.

Sample report